Education
About Us
Working with TipRanks
Follow Us
GRPZ - ETF AI Analysis
Top Page
Invesco S&P SmallCap 600 GARP ETF (GRPZ)
Rating:74Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains so far this year and over the last few months, indicating positive recent momentum.
Leading Holdings Performing Well
Most of the top 10 stocks, such as Powell Industries and several health care names, have delivered strong year-to-date results that support the fund’s returns.
Broad Sector Diversification
Holdings are spread across financials, health care, industrials, consumer sectors, energy, and technology, which helps reduce the impact of weakness in any single industry.
Negative Factors
Small Fund Size
The ETF manages a relatively small amount of assets, which can sometimes lead to higher trading costs and less liquidity for investors.
Higher-Than-Core Expense Ratio
The fund’s fee is noticeably higher than many broad market index ETFs, which can slightly reduce long-term returns.
Heavy U.S. and Sector Focus
With almost all exposure in U.S. stocks and a large tilt toward financials and health care, the fund is vulnerable if these areas of the market struggle.
GRPZ vs. SPDR S&P 500 ETF (SPY)
AUM2.91M
RegionNorth America
Expense Ratio0.35%
Beta0.96
IssuerInvesco
Inception DateMar 27, 2024
Dividend Yield0.89%
Asset ClassEquity
Index TrackedS&P SmallCap 600 GARP Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume645
30 Day Avg. Volume319
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
33.14Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering91
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GRPZ Summary
GRPZ is an ETF that follows the S&P SmallCap 600 GARP Index, focusing on smaller U.S. companies that are growing but still reasonably priced. It holds a mix of sectors like financials, health care, and industrials, with examples including Krystal Biotech and Axos Financial. Someone might invest in GRPZ to seek long-term growth and diversify beyond large, well-known stocks by tapping into the potential of smaller, more agile businesses. A key risk is that small-cap stocks can be more volatile, so the ETF’s price can move up and down more sharply than the overall market.
How much will it cost me?The Invesco S&P SmallCap 600 GARP ETF (GRPZ) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This cost is slightly higher than average for ETFs because it tracks a specific index with a focus on small-cap companies and uses a more selective strategy. It’s still relatively affordable compared to actively managed funds.
What would affect this ETF?GRPZ could benefit from economic growth in the U.S., as small-cap companies often thrive during periods of expansion and innovation, particularly in sectors like Industrials and Technology, which are heavily weighted in the ETF. However, rising interest rates or economic slowdowns could negatively impact small-cap stocks, as these companies may face higher borrowing costs and reduced consumer demand, especially in sectors like Consumer Cyclical and Financials. Regulatory changes or shifts in energy policies could also affect holdings like Helmerich & Payne and International Seaways in the Energy sector.
GRPZ Top 10 Holdings
GRPZ is leaning hard into U.S. small-cap growth stories, with a noticeable tilt toward health care innovators and niche industrial and energy players. Krystal Biotech and TransMedics are two of the fund’s rising stars, helping power returns as their growth narratives gain traction. On the industrial and energy side, Powell Industries, Tidewater, and Cactus are also pulling their weight, adding steady momentum. Catalyst Pharma has been more mixed lately, occasionally losing steam, but overall the fund’s performance is being driven by a broad cast of U.S.-focused small-cap winners rather than a single dominant name.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Powell Industries | 2.32% | $67.33K | $6.82B | 179.38% | 76 Outperform | |
| International Seaways | 2.12% | $61.51K | $3.18B | 70.32% | 72 Outperform | |
| Tidewater | 1.99% | $57.72K | $3.46B | 35.33% | 78 Outperform | |
| Krystal Biotech | 1.88% | $54.39K | $8.35B | 60.80% | 80 Outperform | |
| DXP Enterprises | 1.80% | $52.19K | $2.34B | 43.27% | 71 Outperform | |
| Cactus | 1.78% | $51.51K | $4.55B | -4.51% | 77 Outperform | |
| Catalyst Pharma | 1.73% | $50.01K | $3.03B | 7.81% | 83 Outperform | |
| Worthington Steel, Inc. | 1.69% | $49.08K | $2.30B | 51.81% | 77 Outperform | |
| Ufp Technologies | 1.66% | $48.18K | $1.90B | -5.58% | 75 Outperform | |
| Axos Financial | 1.65% | $47.77K | $5.53B | 39.52% | 78 Outperform |
GRPZ Technical Analysis
Positive
―
Price Trends
28.01
Positive
27.13
Positive
26.21
Positive
Market Momentum
0.35
Positive
57.99
Neutral
53.56
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GRPZ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 28.73, equal to the 50-day MA of 28.01, and equal to the 200-day MA of 26.21, indicating a bullish trend. The MACD of 0.35 indicates Positive momentum. The RSI at 57.99 is Neutral, neither overbought nor oversold. The STOCH value of 53.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRPZ.
GRPZ Peer Comparison
Comparison Results
Performance Comparison
GRPZ
Invesco S&P SmallCap 600 GARP ETF
29.01
3.56
13.99%
FSML
Franklin Small Cap Enhanced ETF
―
―
―
AFSM
First Trust Active Factor Small Cap ETF
―
―
―
BKSE
BNY Mellon US Small Cap Core Equity ETF
―
―
―
STXK
Strive 2000 ETF
―
―
―
FLQS
Franklin LibertyQ U.S. Small Cap Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents